Milestone Pharmaceuticals Reports Third Quarter 2026 Financial Results and Announces Cost-Efficiency Measures Designed to Extend Cash Runway Through AFib-RVR Phase 3 Data
Launch of CARDAMYST® (etripamil) nasal spray marked by steady prescription growth, new prescriber expansion and improving commercial coverage
Covered in this story
Call it yourself
No calls on $MIST yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Milestone Pharmaceuticals →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.